PreCyte launches in the United States
SurgeCare Launches First Pilot of PreCyte to Advance Immune-Based
Precision Medicine in Surgical Care
Paris – December 15th 2025 – SurgeCare (“Surge”), in collaboration with Penn Medicine (The University of Pennsylvania’s Perelman School of Medicine and Health System) and with the support of Incite Health, is launching the first real-world clinical pilot of PreCyte, a novel prognostic test to identify patients at risk for postoperative complications, particularly surgical site infections (SSIs) and postoperative pneumonia.
From Discovery To Clinical Impact
PreCyte is the culmination of over a decade of research and development. It builds upon a predictive immune signature initially discovered at Stanford University by Brice Gaudillière, MD, PhD, co-founder of Surge. In 2023, Franck Verdonk, MD, PhD, Chair of the Scientific & Clinical Board of Surge, led PreCyte’s clinical validation through a multicenter study at five leading European hospitals.
“We started with a scientific discovery and developed it into a tool capable of truly changing patient care,” said Prof. Gaudillière. “PreCyte SSI is reshaping the management of surgical risk by harnessing immune intelligence for proactive clinical decision-making.”
This initial pilot at Penn Medicine is the first global deployment of PreCyte in a clinical setting. Over the next year, approximately 100 surgical patients will participate, integrating the PreCyte test into perioperative care, under the supervision of Jason D. Christie, MD, chief of Pulmonary, Allergy, and Critical Care at Penn.
A Global First: Deploying Precyte Ssi At Penn Medicine
The pilot aligns with Penn Medicine’s broader initiative, the Immune Health Project, which leverages advanced immune profiling to redefine clinical assessment and patient management. By merging Penn Medicine’s clinical expertise with Surge’s innovative biomarker discovery platform, this collaboration seeks to transform scientific breakthroughs in precision diagnostics into scalable clinical solutions. “This study represents a crucial step toward bringing more precision medicine tools into routine clinical practice, ultimately improving patient management and surgical outcomes,” said Allie Greenplate, PhD, the associate director of the Immune Health Project at Penn. “Understanding immune responses at a deeper level is key to reducing post-surgical complications.”
PreCyte’s deployment is bolstered by the analytical expertise of Incite Health, a CLIA-certified laboratory industrializing PreCyte as a Laboratory Developed Test for the U.S. market. Incite Health ensures rigorous sample processing to produce precise, reliable data, enabling SurgeCare to deliver actionable results.
About Incite Health
Incite Health is a CLIA-certified molecular diagnostics laboratory specializing in complex assays. Its focus on innovation ensures diagnostics like PreCyte SSI meet the highest analytical standards while remaining fully compatible with real-world clinical needs.
